Outbreaks of group B meningococcal disease--Florida, 1995 and 1997.
Since 1992, Neisseria meningitidis serogroup B strains have caused several community- and school-based outbreaks in the United States. Response to such outbreaks is difficult because no serogroup B vaccine is licensed currently for use in the United States, and mass chemoprophylaxis has been evaluated only in restricted settings. This report describes the use of mass prophylaxis to control outbreaks of serogroup B meningococcal disease in Florida in two unusual settings: a hotel resort and a nursing home.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001428:Bacterial Vaccines / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D004196:Disease Outbreaks; D005260:Female; D005431:Florida / Q000453:epidemiology; D006801:Humans; D008297:Male; D008589:Meningococcal Infections / Q000453:epidemiology* / Q000517:prevention & control*; D008875:Middle Aged; D009345:Neisseria meningitidis / Q000145:classification / Q000235:genetics / Q000276:immunology; D009735:Nursing Homes; D012111:Residence Characteristics; D012703:Serotyping; D014611:Vaccination
D001428:Bacterial Vaccines